Skip to content

Effect of Guanxin Danshen Dropping Pill on Clinical Anxiety, Depression, Heart Rate Variability and Cardiovascular Prognosis in Patients with Coronary Heart Disease after PCI Combined with Anxiety or Depression

Effect of Guanxin Danshen Dropping Pill on Clinical Anxiety, Depression, Heart Rate Variability and Cardiovascular Prognosis in Patients with Coronary Heart Disease after PCI Combined with Anxiety or Depression

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014291
Enrollment
Unknown
Registered
2018-01-04
Start date
2017-07-01
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Two groups:Placebo and experimental medications

Sponsors

Guangdong General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) voluntarily participate in the trail, signed informed consent; 2) Complies with diagnostic criteria for coronary heart disease (including stable angina pectoris, unstable angina pectoris, non-ST-elevation myocardial infarction, acute ST-segment elevation myocardial infarction) required and completed as required percutaneous coronary intervention (PCI) Surgical patients; 3) PHQ-9 score 5-14 points, or GAD-7 score 5-14 points; 4) women of childbearing age must be treated before the urine pregnancy test and the results were negative, and not in lactation; 5) Aged 18-75 years male or female; 6) can cooperate with the inspection, treatment; 7) Patients have the ability to understand and voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1) cachexia state; or combined lung, liver, kidney, hematopoietic system, the immune system and other serious primary disease and dysfunction; 2) angina pectoris did not relieve or NYHA cardiac function grade IV; 3) recurrent anxiety, depression patients 4) electrolyte imbalance acid-base imbalance; 5) history of epilepsy, or patients with organic mental disorders; 6) other mental illness such as: bipolar affective disorder, schizophrenia and other patients; 7) alcohol and drug abuse and drug addicts within one year; 8) other antidepressant and anxiolytic drugs were taken within four weeks before the test; 9) Pregnant or lactating women, or planned pregnancy; 10) had previous coronary revascularization; 11) participated in other drug clinical trials within 3 months; 12) Researchers believe that they are not suitable for clinical trials; 13) patients with cognitive impairment; 14) patients with suicidal tendencies.

Design outcomes

Primary

MeasureTime frame
the symptom of anxiety and depression;heart rate variety;

Countries

China

Contacts

Public ContactQingshan Geng

Guangdong General Hospital

mahuannovel@163.com+86 13922205818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026